Marsh & McLennan Companies (NYSE:MRSH) & Health In Tech (NASDAQ:HIT) Financial Contrast

Health In Tech (NASDAQ:HIT) and Marsh & McLennan Companies (NYSE:MRSH) are both finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Profitability

This table compares Health In Tech and Marsh & McLennan Companies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health In Tech	N/A	N/A	N/A
Marsh & McLennan Companies	15.60%	31.79%	8.14%

Earnings & Valuation

This table compares Health In Tech and Marsh & McLennan Companies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health In Tech	$30.72 million	3.00	$1.71 million	$0.03	54.00
Marsh & McLennan Companies	$26.98 billion	3.31	$4.06 billion	$8.43	21.90

Marsh & McLennan Companies has higher revenue and earnings than Health In Tech. Marsh & McLennan Companies is trading at a lower price-to-earnings ratio than Health In Tech, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.0% of Marsh & McLennan Companies shares are held by institutional investors. 77.7% of Health In Tech shares are held by company insiders. Comparatively, 0.4% of Marsh & McLennan Companies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Health In Tech and Marsh & McLennan Companies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health In Tech	1	0	0	1	2.50
Marsh & McLennan Companies	1	11	6	1	2.37

Health In Tech currently has a consensus target price of $2.50, indicating a potential upside of 54.32%. Marsh & McLennan Companies has a consensus target price of $216.18, indicating a potential upside of 17.09%. Given Health In Tech’s stronger consensus rating and higher possible upside, research analysts clearly believe Health In Tech is more favorable than Marsh & McLennan Companies.

Risk & Volatility

Health In Tech has a beta of 7.93, meaning that its share price is 693% more volatile than the S&P 500. Comparatively, Marsh & McLennan Companies has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Summary

Marsh & McLennan Companies beats Health In Tech on 9 of the 14 factors compared between the two stocks.

About Health In Tech

Health in Tech, Inc. engages in the provision of insurance technology platforms which offer a marketplace of processes in the healthcare industry. Its services include Stone Mountain Risk, eDIYBS, HI Card, HI Performance Network, and Ancillary Products. The company was founded by Tim Johnson in 2014 and is headquartered in Stuart, FL.

About Marsh & McLennan Companies

Marsh & McLennan Cos., Inc. is a professional services firm, which engages in offering clients advice and solutions in risk, strategy, and people. It operates through the Risk and Insurance Services, and Consulting segments. The Risk and Insurance Services segment is involved in risk management activities, as well as insurance and reinsurance broking and services. The Consulting segment offers health, wealth, and career solutions and products, and specialized management, strategic, economic, and brand consulting services. The company was founded by Henry W. Marsh and Donald R. McLennan in 1871 and is headquartered in New York, NY.